论文部分内容阅读
目的:观察替吉奥联合沙利度胺方案治疗老年晚期胃癌的临床疗效。方法:将2008年1月至2012年12月我院收治的老年晚期胃癌患者43例随机分为替吉奥联合沙利度胺组(研究组)22例和替吉奥组(对照组)21例,比较两组疗效及不良反应。结果:研究组有效率40.9%虽高于对照组的28.6%,但无显著性差异(P>0.05);研究组的疾病控制率和生活质量总改善率均明显高于对照组(P均<0.05);研究组的中位生存期及1年生存率均优于对照组,但差异无统计学意义(P>0.05)。与对照组相比,研究组的恶心呕吐、厌食发生率低,便秘的发生率高,(P均<0.05)。结论:与单药替吉奥化疗相比,替吉奥联合沙利度胺能增加晚期胃癌患者的疾病控制率,改善患者的生活质量,且不良反应轻。
Objective: To observe the clinical efficacy of TIGO combined with thalidomide in the treatment of elderly patients with advanced gastric cancer. Methods: Forty-three patients with advanced gastric cancer admitted to our hospital from January 2008 to December 2012 were randomly divided into two groups: study group (TEG) and thalidomide group (study group) Cases, the two groups were compared efficacy and adverse reactions. Results: Although the effective rate of the study group was 40.9% higher than that of the control group (28.6%), there was no significant difference (P> 0.05). The disease control rate and the total quality of life improvement rate of the study group were significantly higher than those of the control group (P < 0.05). The median survival time and 1-year survival rate of the study group were better than those of the control group, but the difference was not statistically significant (P> 0.05). Compared with the control group, the study group had nausea and vomiting, low incidence of anorexia, and high incidence of constipation (all P <0.05). CONCLUSIONS: Compared with single-agent treatment of tegaserod, tegaserod combined with thalidomide can increase the disease control rate and improve the quality of life of patients with advanced gastric cancer, with less adverse reactions.